Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dartmouth-Hitchcock Medical Center
The study treatment for this protocol is
* Loading dose of Cetuximab 400 mg/m2
* Weekly Cetuximab 250 mg/m2
* Bi-weekly Gemcitabine 50 mg/m2
* Daily Radiation for 28 fractions
* CT scan four weeks after completion of treatment
* Evaluation by surgeon for resectability
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic proof of pancreatic adenocarcinoma
Clinical stage I, II, or III disease
Radiographically measurable disease
Tumor tissue for epidermal growth factor receptor (EGFR) status by immunohistochemistry
Signed protocol consent
Karnofsky performance status of at least 70%
Age \> or = to 18 years
Patients must either not be of child bearing potential or have a negative pregnancy test within 72 hours of treatment.
Prior therapy which affects or targets the EGF pathway
Prior severe infusion reaction to a monoclonal antibody
Any concurrent chemotherapy not indicated in the study protocol or any other investigational agents
Any previous chemotherapy or abdominal or pelvic radiotherapy
No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or malignancy for which the patient has been disease free for five years.
Any severe pre-existing medical or psychiatric condition, which, in the opinion of the attending physician, will interfere with safe and appropriate treatment and follow-up on study
